PubRank

Paolo Neviani

Author PubWeight™ 31.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010 4.07
2 Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009 2.68
3 Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013 2.16
4 Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010 2.06
5 Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013 2.03
6 Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007 1.72
7 PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013 1.72
8 Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010 1.64
9 A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2005 1.56
10 Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008 1.37
11 High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007 1.19
12 Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 2006 1.19
13 The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med 2007 1.15
14 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013 1.14
15 From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007 1.11
16 Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2007 1.07
17 Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 2007 1.06
18 Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 2009 0.99
19 SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest 2014 0.86
20 Triggering of guanosine self-assembly by light. Angew Chem Int Ed Engl 2010 0.84
21 Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia. Cell Cycle 2012 0.75
22 Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies. Mini Rev Med Chem 2014 0.75
23 Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent. Drug Deliv 2013 0.75